Neil Stevenson
About Neil Stevenson
Neil Stevenson is the CMC / Process Chemistry Manager at BenevolentAI, with a strong background in genotoxin control, regulatory strategy, and analytical chemistry.
Current Title and Role
Neil Stevenson is currently serving as the CMC / Process Chemistry Manager at BenevolentAI. He joined BenevolentAI in June 2021. In this role, Neil is involved in the integration of AI with human expertise to aid in the discovery of new medicines. His work focuses on process chemistry and the development of new methodologies for drug discovery.
Educational Background
Neil Stevenson completed his Doctor of Philosophy (PhD) in Organic Chemistry from The University of Sheffield, where he studied from 2003 to 2006. Prior to this, he earned his MChem in Chemistry with Study in Industry from the same institution, studying from 1999 to 2003. His academic background laid a strong foundation for his expertise in chemistry and drug development.
Previous Experience at GlaxoSmithKline
Neil Stevenson has a long tenure at GlaxoSmithKline, where he worked for a total of 14 years. From 2010 to 2021, he served as an Investigator, and from 2007 to 2010, he was a Senior Scientist based in Stevenage, United Kingdom. During his time at GSK, Neil gained experience in various domains, including analytical chemistry, genotoxin control, and regulatory strategy. He was involved in taking projects through the entire drug development lifecycle.
Specialized Expertise
Neil Stevenson has a strong background in genotoxin control and regulatory strategy, which are critical aspects of pharmaceutical development. His expertise extends to various facets of process chemistry and analytical chemistry. He is particularly passionate about people leadership and continuous development, which have been central themes throughout his career.
Passion and Interests
Neil Stevenson is passionate about integrating artificial intelligence with human expertise to discover new medicines. This aligns with his current role at BenevolentAI, where leveraging AI for drug discovery is a key focus. He also shows a keen interest in leadership and continuous development, reflecting his commitment to contributing to advancements in the pharmaceutical industry.